Gilead Sciences' Q1 2025 earnings report shows a slight decline in product sales, primarily due to lower Veklury sales and oncology inventory issues. The HIV division remains Gilead's strongest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback